Axolotl Biologix, an innovator in regenerative medicine technologies that improve patient outcomes with less pain and lower costs, today announced that it has begun shipping its second amniotic allograft product, AxoBioMembrane™, to meet a wide range of wound care needs.Continue reading
Category Archives: AZBio News
Castle Biosciences’ DecisionDx-Melanoma Test Accurately Predicts Metastatic Risk in Patients with Head and Neck Melanoma
Data was presented at the American College of Mohs Surgery 49th Annual Meeting
Distinguished Cardiologist and Scientist Dr. Guy Reed Named Dean of the UA College of Medicine – Phoenix
Dr. Reed brings impressive record of leadership, teaching, research and clinical careContinue reading
TGen-HonorHealth study: High rate of tumor shrinkage among pancreatic cancer patients
Results of the Triplet Clinical Trial at HonorHealth Research Institute based on the TGen Triple research presented at ASCO-GI symposium in San FranciscoContinue reading
BD To Acquire Bard For $24 Billion
On on April 23, 2017, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.Continue reading
ASU faculty chosen for prestigious Mayo Clinic summer residency
Mayo Clinic and Arizona State University Alliance for Health Care has chosen eight Alliance Fellows to be part of the inaugural Faculty in Residence program.Continue reading
Paradigm Diagnostics Announces Active Clinical Trial Site Enrollment for Personalized Medicine Cancer Registry
Paradigm Diagnostics announces the launch and IRB approval of the Paradigm registry to allow physicians to better collect, share, and visualize data to help advance personalized medicine in oncology.
Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases
Tucson, AZ, April 12, 2017 Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis. This antibody has been validated for use in a dual stain with the VENTANA Basal Cell Cocktail (34ßE12+p63) to aid in distinguishing morphologically difficult cases as benign, atypical or cancerous on a single slide. The assay is an in vitro diagnostic (IVD) primary antibody for use on the VENTANA BenchMark IHC/ISH series of automated slide stainers.Continue reading